Montelukast

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Bronchial Asthma

Conditions

Bronchial Asthma, Food Allergy, Children

Trial Timeline

Mar 1, 2013 → May 1, 2016

NCT ID

NCT01618929

About Montelukast

Montelukast is a approved stage product being developed by Merck for Bronchial Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT01618929. Target conditions include Bronchial Asthma, Food Allergy, Children.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01618929	Approved	Completed	Mar 1, 2013	May 1, 2016	Bronchial Asthma
NCT01027806	Approved	Terminated	Jul 1, 2010	Aug 1, 2014	Obstructive Sleep Apnea
NCT00492102	Phase 1	Completed	Mar 1, 2007	Jun 1, 2011	Bronchopulmonary Dysplasia
NCT00559546	Approved	Completed	Mar 1, 2007	Jul 1, 2007	Seasonal Allergic Rhinitis
NCT00721240	Approved	Completed	Feb 1, 2006	Jun 1, 2009	Asthma
NCT00148603	Pre-clinical	Completed	Sep 1, 2005	Dec 1, 2006	Eosinophilic Gastroenteritis
NCT00934713	Approved	Completed	Sep 1, 2004	Apr 1, 2008	Lung Disease, Obstructive
NCT00116324	Phase 3	Completed	Apr 1, 2003	Dec 1, 2006	Asthma

Competing Products

20 competing products in Bronchial Asthma

See all competitors

Product	Company	Stage	Hype Score
Tacrolimus	Astellas Pharma	Phase 2	52
tacrolimus	Astellas Pharma	Phase 2	52
Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation) + Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1 + Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2 + Placebo	Cipla	Phase 3	77
90 mcg Reference Product + 180 mcg Reference Product + 90 mcg Test Product + Placebo	Cipla	Phase 3	77
Fluticasone propionate/salmeterol 100/50 µg + Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT	Cipla	Phase 3	77
Test Product + Reference Product + Placebo	Aurobindo Pharma	Phase 3	77
Albuterol Sulfate HFA 0.09 mg (Reference) + Albuterol Sulfate HFA 0.18 mg (Reference) + Albuterol Sulfate HFA 0.09 mg (Test) + Albuterol Sulfate HFA 0.18 mg (Test) + Placebo	Aurobindo Pharma	Phase 3	77
Fluticasone propionate Inhalation Aerosol 44 mcg + FLOVENT HFA 44 mcg + Matching Placebo inhaler	Glenmark Pharmaceuticals	Phase 3	77
Symbicort Turbuhaler + Symbicort pMDI + Pulmicort Turbuhaler	AstraZeneca	Phase 3	77
Roflumilast	AstraZeneca	Phase 3	77
Roflumilast	AstraZeneca	Phase 2/3	65
Symbicort (budesonide/formoterol) Turbuhaler + Conventional treatment	AstraZeneca	Phase 3	77
Ciclesonide	AstraZeneca	Phase 3	77
Montelukast plus prednisolone + Prednisolone	Merck	Phase 2	52
Formoterol fumerate + fenoterol/ipratropium bromide	Novartis	Approved	85
inhaled corticosteroid therapy	Novartis	Phase 1/2	41
PF-00610355 + PF - 00610355 + PF - 00610355	Pfizer	Phase 2	51
Nivolumab	Bristol Myers Squibb	Phase 2	51
HSK31858 + Placebo	Haisco Pharmaceutical Group	Phase 2	49
HSK31858 + Placebo	Haisco Pharmaceutical Group	Phase 2	49

Other Products from Merck

DuleraApproved

ImipenemApproved

Mavenclad®Approved

raltegravir + PlaceboApproved

alendronate sodiumApproved